You are here

Home

Clinical Trials: Central Nervous System Diseases

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Friday, October 11, 2019 - 12:00
IpsiHand System for Rehabilitation of the Arm and Hand After Stroke
Conditions:   Stroke;   Hemiparesis
Intervention:   Device: IpsiHand Treatment
Sponsors:   Columbia University;   Neurolutions, Inc.
Not yet recruiting
Posted: Tuesday, October 1, 2019 - 12:00
Safety and Tolerability of RTX-134 in Adults With Phenylketonuria
Condition:   Phenylketonurias
Intervention:   Drug: RTX-134
Sponsor:   Rubius Therapeutics
Recruiting
Posted: Friday, September 20, 2019 - 12:00
Estimation of the Safety and Efficiency Transfusion of HLA Matched CBU in Patients With CP
Condition:   Cerebral Palsy
Interventions:   Biological: Low HLA group CBU infusion;   Biological: High HLA group CBU infusion;   Other: Standard therapy
Sponsors:   State-Financed Health Facility "Samara Regional Medical Center Dinasty";   INBIO, LLC
Recruiting
Posted: Friday, September 20, 2019 - 12:00
Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke
Condition:   Acute Ischemic Stroke
Intervention:   Biological: UMC119-06
Sponsor:   Meridigen Biotech Co., Ltd.
Not yet recruiting
Posted: Wednesday, September 18, 2019 - 12:00
Effect of Different Transplantation Time for Mesenchymal Stem Cells(MSCs) of Cerebral Infarction Patients
Conditions:   Infarction, Middle Cerebral Artery;   Infarction, Anterior Cerebral Artery;   Cerebral Infarction;   Stroke, Ischemic;   Acute Stroke
Interventions:   Biological: human umbilical cord mesenchymal stem cells;   Biological: Placebo;   Other: standardized treatment
Sponsor:   Shanghai East Hospital
Recruiting
Posted: Thursday, September 12, 2019 - 12:00
An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 (Autologous Adipose-derived Stem Cells) in Patients With Chronic Stroke
Condition:   Chronic Stroke
Intervention:   Drug: GXNPC1
Sponsor:   Gwo Xi Stem Cell Applied Technology Co., Ltd.
Not yet recruiting
Posted: Tuesday, August 13, 2019 - 12:00
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
Condition:   Acute Spinal Cord Injury
Interventions:   Drug: Normal Saline along with standard treatment;   Drug: PMZ-1620 along with standard treatment
Sponsor:   Pharmazz, Inc.
Recruiting
Posted: Monday, August 12, 2019 - 12:00
PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
Conditions:   Alzheimer Disease;   Dementia
Interventions:   Drug: Normal Saline along with standard treatment;   Drug: PMZ-1620 (sovateltide) along with standard treatment
Sponsor:   Pharmazz, Inc.
Recruiting
Posted: Tuesday, August 6, 2019 - 12:00
Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
Conditions:   Cerebral Ischemia;   Cerebral Infarction;   Stroke, Acute
Interventions:   Drug: Normal Saline along with standard treatment;   Drug: PMZ-1620 (sovateltide) along with standard treatment
Sponsor:   Pharmazz, Inc.
Not yet recruiting
Posted: Wednesday, July 31, 2019 - 12:00
Alzheimer's Disease Stem Cells Multiple Infusions
Condition:   Alzheimer Disease
Interventions:   Biological: 100 million cells allogeneic hMSC;   Biological: 200 million cells allogeneic hMSC
Sponsor:   Bernard (Barry) Baumel
Not yet recruiting

Pages